…
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Standard Biotools Inc develops instruments, reagents and software for single-cell genomics and proteomics used by research and clinical labs. Long-term growth may be driven by expanding demand for single-cell and spatial biology, recurring consumables and adoption of multi-omics workflows, and the company appears positioned to benefit from researchers' shift toward higher-resolution cell analysis.
Key risks include intense competition from larger genomics vendors, rapid technological change that could erode product advantages, and variability in capital-equipment purchases and consumable demand that could reduce revenue visibility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -96.70M | -138.31M | -74.20M | -192.93M | -63.66M |
| Net income | -74.90M | -138.88M | -74.66M | -190.10M | -59.24M |
| Selling general administrative | 109.86M | 156.61M | 98.88M | 114.76M | 98.89M |
| Gross profit | 42.54M | 84.26M | 50.45M | 37.05M | 77.27M |
| Reconciled depreciation | 10.98M | 16.86M | 14.89M | 15.03M | 15.57M |
| Ebit | -96.68M | -135.00M | -69.64M | -116.20M | -67.46M |
| Ebitda | -89.69M | -118.14M | -54.46M | -113.49M | -67.46M |
| Depreciation and amortization | 6.98M | 16.86M | 15.18M | 2.72M | 23.20M |
| Non operating income net other | - | - | - | 1.25M | - |
| Operating income | -93.31M | -175.24M | -76.60M | -116.20M | -67.46M |
| Other operating expenses | 178.64M | 349.67M | 182.94M | 214.15M | 198.04M |
| Interest expense | 0.03M | 3.32M | 4.57M | 4.33M | 3.82M |
| Tax provision | -37.88M | 0.57M | 0.68M | -2.83M | -4.42M |
| Interest income | 9.18M | 20.20M | 5.57M | 64.41M | 3.82M |
| Net interest income | 9.15M | 16.88M | -4.66M | -4.33M | -3.82M |
| Extraordinary items | -16.07M | -47.95M | - | - | - |
| Income tax expense | -37.88M | 0.57M | 0.45M | -2.83M | -4.42M |
| Total revenue | 85.33M | 174.43M | 106.34M | 97.95M | 130.58M |
| Total operating expenses | 135.85M | 259.50M | 127.05M | 153.26M | 144.72M |
| Cost of revenue | 42.79M | 90.17M | 55.89M | 60.90M | 53.31M |
| Total other income expense net | -3.40M | 36.92M | 2.40M | -76.72M | 3.80M |
| Net income from continuing ops | -58.83M | -138.88M | -75.72M | -190.10M | -59.24M |
| Net income applicable to common shares | -74.90M | -184.90M | -74.66M | -190.10M | -59.24M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 567.75M | 612.34M | 323.07M | 390.31M | 275.21M |
| Intangible assets | - | 28.95M | 1.41M | 12.60M | 27.93M |
| Other current assets | 233.28M | 8.66M | 3.13M | 4.28M | 4.47M |
| Total liab | 143.46M | 140.62M | 159.87M | 471.78M | -54.10M |
| Total stockholder equity | 424.29M | 471.72M | 163.20M | -81.47M | 94.60M |
| Other current liab | 58.46M | 27.22M | 20.57M | 15.33M | 13.59M |
| Common stock | 0.40M | 0.40M | 0.08M | -81.47M | 0.08M |
| Capital stock | 0.40M | 0.40M | 0.08M | -81.47M | 0.08M |
| Retained earnings | -1260.55M | -1185.65M | -1000.75M | -926.10M | -736.00M |
| Other liab | - | - | - | 20.19M | 29.29M |
| Good will | - | 111.30M | 106.32M | 106.25M | 106.38M |
| Other assets | - | - | - | 3.11M | 2.43M |
| Cash | 118.21M | 166.73M | 51.70M | 81.31M | 28.45M |
| Cash and equivalents | - | - | - | 81.31M | 28.45M |
| Total current liabilities | 108.31M | 65.89M | 109.33M | 43.44M | -54.10M |
| Current deferred revenue | 38.95M | 18.59M | 15.67M | 14.44M | 15.48M |
| Net debt | -87.39M | -133.73M | 46.51M | 21.35M | 83.20M |
| Short term debt | 5.49M | 6.23M | 63.85M | 5.76M | 9.89M |
| Short long term debt | - | - | 59.53M | 2.08M | 6.84M |
| Short long term debt total | 30.83M | 33.00M | 98.21M | 102.66M | 111.65M |
| Other stockholder equity | 1685.93M | 1655.75M | 854.84M | 616.74M | 831.42M |
| Property plant equipment | - | - | - | 59.53M | 65.15M |
| Total current assets | 454.26M | 375.88M | 158.22M | 208.81M | 72.07M |
| Long term investments | 25.70M | 0.00M | - | - | - |
| Net tangible assets | - | - | - | 110.94M | -40.97M |
| Short term investments | 69.36M | 126.15M | 63.19M | 84.47M | - |
| Net receivables | 13.43M | 33.61M | 19.66M | 17.28M | 18.32M |
| Long term debt | 0.30M | 0.30M | 3.98M | 62.81M | 64.21M |
| Inventory | 19.98M | 40.74M | 20.53M | 21.47M | 20.82M |
| Accounts payable | 5.41M | 12.28M | 9.24M | 7.91M | 10.60M |
| Accumulated other comprehensive income | -1.49M | 1.23M | -2.22M | -1.90M | -0.91M |
| Common stock total equity | - | - | - | 0.08M | - |
| Retained earnings total equity | - | - | - | -926.10M | - |
| Non currrent assets other | 3.15M | 24.83M | 1.48M | 3.11M | 3.69M |
| Non current assets total | 113.49M | 236.46M | 164.85M | 181.50M | 203.15M |
| Capital lease obligations | 30.53M | 32.70M | 34.70M | 37.76M | 40.60M |
| Long term debt total | - | - | - | 62.81M | 64.21M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 40.71M | 363.17M | 73.60M | -88.13M | -11.95M |
| Change to liabilities | - | - | - | -8.75M | -1.93M |
| Total cashflows from investing activities | 24.77M | 363.17M | 20.24M | -88.13M | -11.95M |
| Net borrowings | 0.00M | -63.19M | -2.08M | 5.62M | 16.34M |
| Total cash from financing activities | 0.57M | -102.62M | -6.81M | 230.76M | 15.96M |
| Change to operating activities | - | - | - | -1.83M | -19.95M |
| Net income | -74.90M | -138.88M | -74.66M | -190.10M | -59.24M |
| Change in cash | -48.17M | 116.32M | -29.82M | 52.86M | -40.07M |
| Begin period cash flow | 168.82M | 52.50M | 82.32M | 29.47M | 69.54M |
| End period cash flow | 120.65M | 168.82M | 52.50M | 82.32M | 29.47M |
| Total cash from operating activities | -74.35M | -143.45M | -43.29M | -89.37M | -44.06M |
| Issuance of capital stock | - | 0.00M | 0.00M | 225.00M | 0.00M |
| Depreciation | 1.72M | 16.86M | 15.18M | 15.03M | 11.92M |
| Other cashflows from investing activities | -5.00M | 92.88M | 23.07M | -84.30M | 1.32M |
| Change to inventory | -11.52M | -9.88M | -4.91M | -8.47M | 20.82M |
| Change to account receivables | -1.36M | 8.97M | -2.99M | 1.06M | 18.32M |
| Sale purchase of stock | 1.05M | -40.95M | -5.41M | -0.56M | 1.49M |
| Other cashflows from financing activities | -0.48M | 1.52M | 0.69M | 13.16M | 15.96M |
| Change to netincome | - | - | - | 30.67M | 18.42M |
| Capital expenditures | 8.30M | 8.36M | 2.83M | 3.83M | 13.26M |
| Change receivables | - | - | - | 1.06M | - |
| Cash flows other operating | - | - | - | 70.37M | - |
| Cash and cash equivalents changes | - | - | - | 53.26M | - |
| Change in working capital | -44.98M | -12.08M | 1.79M | -15.48M | 49.75M |
| Stock based compensation | 29.61M | 31.73M | 13.12M | 14.88M | 4.92M |
| Other non cash items | 14.20M | -41.08M | 1.28M | 86.30M | -55.74M |
| Free cash flow | -82.65M | -151.81M | -46.12M | -93.19M | -57.33M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LAB Standard Biotools Inc |
0.03 4.29% |
0.64 | - | - | 3.25 | 0.50 | 0.27 | -19.22 |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Vikram Jog | Chief Financial Officer | 1956 |
| Dr. Michael Egholm Ph.D. | Pres, CEO & Director | 1963 |
| Dr. Stephen R. Quake D.phil., Ph.D. | Co-Founder & Chairman of Advisory Board | 1970 |
| Mr. Hanjoon Kim | Chief Operating Officer | 1971 |
| Mr. Andrew Quong Ph.D. | Chief Science Officer | NA |
| Mr. Peter DeNardo | Investor Relations | NA |
| Mr. Rafael Aguirre-Sacasa | Acting Gen. Counsel | NA |
| Mark Spearman | Sr. Director of Corp. Communications | NA |
| Ms. Angela Peters | Chief HR Officer | NA |
| Dr. David A. King Ph.D. | Sr. VP of Global R&D | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.